Amalgamated Bank decreased its holdings in shares of DaVita Inc. (NYSE:DVA – Free Report) by 4.5% in the 4th quarter, Holdings Channel reports. The fund owned 9,583 shares of the company’s stock after selling 449 shares during the period. Amalgamated Bank’s holdings in DaVita were worth $1,433,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in DVA. Transcendent Capital Group LLC acquired a new position in DaVita during the 3rd quarter worth approximately $25,000. Quarry LP bought a new stake in shares of DaVita during the third quarter worth $60,000. Venturi Wealth Management LLC increased its holdings in shares of DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after buying an additional 152 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after acquiring an additional 169 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of DaVita by 39.7% during the 4th quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after acquiring an additional 131 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.
DaVita Stock Performance
Shares of DVA stock opened at $142.82 on Tuesday. The stock has a market capitalization of $11.43 billion, a PE ratio of 13.30, a PEG ratio of 1.07 and a beta of 0.94. The business’s 50 day simple moving average is $160.45 and its 200 day simple moving average is $158.18. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a one year low of $124.78 and a one year high of $179.60.
Wall Street Analyst Weigh In
Several research firms have commented on DVA. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $166.33.
Read Our Latest Stock Report on DaVita
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- How Technical Indicators Can Help You Find Oversold Stocks
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Transportation Stocks Investing
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.